← Leaderboards
David Polsky
New York University School Of Medicine
$5,279,409
Attributed
$5,279,409
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $643K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,152,742 · 8
FDA$1,126,667 · 1
By mechanism
R21$1,523,049 · 4
UH3$1,360,895 · 1
U01$1,126,667 · 1
UH2$770,161 · 2
K08$498,637 · 1
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Iman Osman$8,470,073
- Eva Hernando$15,270,218
- Amanda W. Lund$5,973,567
- William N Rom$26,662,104
- Jill P Buyon$29,367,681
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaGene MutationTumorRecurrenceFollow-UpMutationMolecularBraf GeneMetastatic MelanomaGenesAdjuvant TherapyMalignant NeoplasmsDetectionSpecimenMonitorSensitivity And SpecificityValidationBiological MarkersMutantDisease ProgressionBaseClinicSamplingClinical Trials
Grant awards (23)
Analytical and Clinical Validation of an EPIC 900K v2 array-based methylation assay to predict recurrence in stage II melanoma$310,185
UH2 · FY2025 · CA · contact PI
TERT epigenetic and genomic variants in stage II melanoma as biomarkers of outcome$188,198
R21 · FY2024 · CA · contact PI
TERT epigenetic and genomic variants in stage II melanoma as biomarkers of outcome$237,724
R21 · FY2023 · CA · contact PI
Validation of circulating tumor DNA assays for detection of metastatic melanoma$497,571
UH3 · FY2020 · CA · contact PI
Validation of circulating tumor DNA assays for detection of metastatic melanoma$33,851
UH3 · FY2020 · CA · contact PI
Validation of circulating tumor DNA assays for detection of metastatic melanoma$405,723
UH3 · FY2019 · CA · contact PI
Validation of circulating tumor DNA assays for detection of metastatic melanoma$423,750
UH3 · FY2018 · CA · contact PI
Validation of circulating tumor DNA assays for detection of metastatic melanoma$248,101
UH2 · FY2017 · CA · contact PI
Evaluation of TERT promoter mutations as melanoma biomarkers in tumors and plasma$221,198
R21 · FY2016 · CA · contact PI
Validation of circulating tumor DNA assays for detection of metastatic melanoma$211,875
UH2 · FY2016 · CA · contact PI
Evaluation of TERT promoter mutations as melanoma biomarkers in tumors and plasma$184,331
R21 · FY2015 · CA · contact PI
Blood-based detection of BRAF and NRAS DNA as biomarkers in patients with stage I$281,667
U01 · FY2013 · FD · contact PI
Blood-based detection of BRAF and NRAS DNA as biomarkers in patients with stage I$422,500
U01 · FY2012 · FD · contact PI
Blood-based detection of BRAF DNA as a biomarker in metastatic melanoma patients$220,545
R21 · FY2012 · CA · contact PI
Blood-based detection of BRAF and NRAS DNA as biomarkers in patients with stage I$422,500
U01 · FY2011 · FD · contact PI
Blood-based detection of BRAF DNA as a biomarker in metastatic melanoma patients$183,788
R21 · FY2011 · CA · contact PI
Relevance of circulating mutant BRAF DNA in melanoma$141,925
R21 · FY2006 · CA · contact PI
Relevance of circulating mutant BRAF DNA in melanoma$145,340
R21 · FY2005 · CA
ALTERATIONS OF CELL CYCLE CONTROL IN MELANOCYTIC LESIONS$126,090
K08 · FY2003 · AR
ALTERATIONS OF CELL CYCLE CONTROL IN MELANOCYTIC LESIONS$126,090
K08 · FY2002 · AR
ALTERATIONS OF CELL CYCLE CONTROL IN MELANOCYTIC LESIONS$126,090
K08 · FY2001 · AR
ALTERATIONS OF CELL CYCLE CONTROL IN MELANOCYTIC LESIONS$90,275
K08 · FY2000 · AR
ALTERATIONS OF CELL CYCLE CONTROL IN MELANOCYTIC LESIONS$30,092
K08 · FY2000 · AR